pharma · Bladder (Urothelial, Transitional Cell) Cancer · Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) · RLMD
RELMADA THERAPEUTICS
RELMADA THERAPEUTICS, INC.
RELMADA THERAPEUTICS patent portfolio — 7 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Coral Gables, USA
- Founded
- 2004
- Employees
- 33
- Programs
- 6
- Drugs
- 5
- Patents
- 7
RELMADA THERAPEUTICS patents
7 pharmaceutical patents indexed for RELMADA THERAPEUTICS. 0 expire within 24 months.
RELMADA THERAPEUTICS has 7 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 11607407
Dermal pharmaceutical compositions of 1-methyl-2′,6′-pipecoloxylidide and method of use
granted -
US 10624887
Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14,-diol
granted -
US 9855226
d-methadone for the treatment of psychiatric symptoms
granted -
US 9468611
d-Methadone for the treatment of psychiatric symptoms
granted -
US 9364430
Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14-diol
granted -
US 9125833
Multimodal abuse resistant and extended release opioid formulations
granted -
US 8329744
Methods of preventing the serotonin syndrome and compositions for use thereof
granted
Frequently asked questions
How many patents does RELMADA THERAPEUTICS have?
7 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do RELMADA THERAPEUTICS patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.